Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted in 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tourmaline Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tourmaline Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tourmaline Bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Siegall Clay BDirector–Oct 28, 20251
Middlekauff W BradfordCBO, GC and Secretary0Oct 28, 20251
McDade MarkDirector0IndirectOct 28, 20251
Castelein CaleyDirector0IndirectOct 28, 20252
Srivastava SapnaDirector0Oct 28, 20251
Kantoff AaronDirector0Oct 28, 20252
Kulkarni Sandeep ChidambarCEO0IndirectOct 28, 20252
Johnson Kevin BruceChief Regulatory Officer0Oct 28, 20252
Jones Susan DanaChief Technology Officer0Oct 28, 20251
Thiara ParvinderDirector0Oct 28, 20251
Robinson Ryan F.CFO0Oct 28, 20252
Chyung Yung H.Chief Medical Officer56,836Oct 23, 20230
Fenton Mary KayChief Financial Officer68,054Jul 6, 20230
Requadt ScottOther: Former Chief Executive Officer578,403Jul 6, 20230
Nader FrancoisDirector386,932IndirectJun 14, 20230
Smith Karen L.Director–Jun 14, 20230
Shah GauravDirector–Jun 14, 20230
Mackay GeoffreyDirector–Jun 14, 20230
Ildstad SuzanneDirector3,771,392Jun 14, 20230
Agarwala SandipDirector–Jun 14, 20230
Zdanowski MichaelChief Technology Officer121,470Feb 3, 20230
Krieger NancyChief Medical Officer330,233Feb 3, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 22, 2024 (view filing)Aug 211 dayKulkarni Sandeep ChidambarCEOPPurchase+1.78K$14.85+$26.4K+34.1%7.00K after
Aug 20, 2024 (view filing)Aug 164 daysKulkarni Sandeep ChidambarCEOPPurchase+5.22K$13.79+$72.0KNew position5.22K after
Jan 31, 2024 (view filing)Jan 292 daysMcDade MarkDirectorPPurchase+100.0K$32.50+$3.25M+28.7%448.4K after
Nov 20, 2023 (view filing)Nov 173 daysKulkarni Sandeep ChidambarCEOPPurchase+4.00K$16.99+$68.0K+0.6%729.7K after
Nov 20, 2023 (view filing)Nov 173 daysThiara ParvinderDirectorPPurchase+1.00K$17.31+$17.3K+1.2%83.8K after
Oct 27, 2023 (view filing)Oct 25-272 daysCastelein CaleyDirectorPPurchase+20.0K$14.03+$280.6K+4.0%516.5K after2 lots
Oct 26, 2023 (view filing)Oct 24-262 daysKulkarni Sandeep ChidambarCEOPPurchase+9.65K$11.49+$110.9K+1.3%725.7K after2 lots
Oct 26, 2023 (view filing)Oct 242 daysKantoff AaronDirectorPPurchase+7.50K$11.86+$89.0K+19.8%45.4K after
Oct 26, 2023 (view filing)Oct 24-252 daysThiara ParvinderDirectorPPurchase+7.00K$11.08+$77.5K+9.2%82.8K after2 lots
Jun 14, 2023 (view filing)Jun 12-142 daysIldstad SuzanneDirectorSSale−44.0K$2.55−$112.3K−1.2%3.77M after3 lots10b5-1
Jun 9, 2023 (view filing)Jun 7-92 daysIldstad SuzanneDirectorSSale−141.1K$2.43−$342.6K−3.6%3.82M after3 lots10b5-1
Jun 7, 2023 (view filing)Jun 5-62 daysIldstad SuzanneDirectorSSale−33.4K$2.53−$84.4K−1.2%2.76M after2 lots10b5-1
Jun 5, 2023 (view filing)Jun 1-24 daysIldstad SuzanneDirectorSSale−31.5K$2.53−$79.8K−1.1%2.79M after2 lots10b5-1
Apr 25, 2023 (view filing)Apr 214 daysIldstad SuzanneDirectorSSale−15.0K$2.35−$35.3K−0.5%2.82M after10b5-1
Apr 21, 2023 (view filing)Apr 19-202 daysIldstad SuzanneDirectorSSale−68.7K$2.28−$156.5K−2.4%2.84M after2 lots10b5-1
Apr 19, 2023 (view filing)Apr 17-182 daysIldstad SuzanneDirectorSSale−149.0K$2.14−$319.3K−4.9%2.91M after2 lots10b5-1
Apr 7, 2023 (view filing)Mar 1721 daysIldstad SuzanneDirectorSSale−10.4K$2.06−$21.5K−0.3%3.05M afterAmended10b5-1
Apr 7, 2023 (view filing)Mar 335 daysIldstad SuzanneDirectorSSale−6.81K$2.06−$14.0K−0.2%3.06M afterAmended10b5-1
Apr 7, 2023 (view filing)Mar 137 daysIldstad SuzanneDirectorSSale−29$2.05−$59.450.0%3.07M afterAmended10b5-1
Apr 7, 2023 (view filing)Feb 2145 daysIldstad SuzanneDirectorSSale−3.50K$2.05−$7.17K−0.1%3.07M afterAmended10b5-1
Apr 7, 2023 (view filing)Feb 16-1750 daysIldstad SuzanneDirectorSSale−6.55K$2.05−$13.5K−0.2%3.07M afterAmended2 lots10b5-1
Sep 13, 2022 (view filing)Jul 19-2156 daysNader FrancoisDirectorPPurchase+138.5K$3.61+$500.0KNew position138.5K afterAmended3 lots
Aug 23, 2022 (view filing)Aug 221 dayIldstad SuzanneChief Scientific OfficerSSale−525.0K$2.80−$1.47M−14.6%3.08M after
Aug 2, 2022 (view filing)Jul 294 daysRequadt ScottChief Executive OfficerPPurchase+39.4K$4.25+$167.4K+8.4%508.7K after
Jul 28, 2022 (view filing)Jul 26-282 daysRequadt ScottChief Executive OfficerPPurchase+8.62K$4.24+$36.6K+1.9%469.3K after2 lots
Jul 26, 2022 (view filing)Jul 224 daysRequadt ScottChief Executive OfficerPPurchase+9.44K$3.75+$35.4K+2.1%460.7K after